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Target patients for partial hepatectomy and relationship between
PLT and prognosis in BCLC B HCC
recently reported [1]. A careful look at this retrospective study
[3] showed aspartate amino-transferase to platelet ratio (APRI)
but not PLT, to be associated with poor prognosis in patients with
HCC. On multivariate analysis, APRI (not PLT) and other 3 factors
were associated with both poor DFS and OS. Thus, APRI and PLT
should not be confused. Further studies are required to determine
the relationship between PLT with prognosis of HCC.
As TACE is not a curative therapy, and residual diseases are
commonly left after TACE, it is difﬁcult to use DFS in the TACE
group. As clinical practice guidelines for HCC suggest OS to be
used as a primary endpoint for randomized comparative trials
in HCC research [1], we did not compare the RFS between the
two groups. All the enrolled patients in our study had multiple
tumors; it is not surprising that the recurrence rate was high in
the PH group. However, the OS curves clearly showed better
survival outcomes of patients who received PH.
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Letters to the EditorTo the Editor:
The most common etiology of hepatocellular carcinoma (HCC) in
China is hepatitis B virus infection, which is in marked contrast to
the United Kingdom with common etiologies like alcoholism,
non-alcoholic fatty liver disease, and hepatitis C virus infection.
There is no doubt that a randomized comparative trial (RCT),
involving a large number of patients with HCC, would provide a
clearer answer to the point raised by Metussin et al., in their Let-
ter to the Editor. Unfortunately, such a study would be difﬁcult to
carry out. Although in our study there were more Child-Pugh B
patients in the TACE group, there was no signiﬁcant difference
between the 2 groups. In response to the criticisms about the
exclusion from our study of patients 70 years or older, this RCT
was conducted on a selected group of patients, who were suitable
to undergo both partial hepatectomy (PH) and TACE, and chrono-
logical age of over 70 years alone has never been a contraindica-
tion to these treatments in our center.
Clinical practice guidelines for HCC state that drug-eluting
beads (DEB) had similar response rates when compared with con-
ventional TACE [1]. However, DEB is recommended for its less
systemic adverse events. Although many clinical studies on DEB
have been reported, the beneﬁts on survival of DEB, when com-
pared with conventional TACE, remain controversial. Until now,
there has not been any clinical comparative trial which compares
DEB with PH on survival in patients with BCLC B stage HCC. A
study [2] showed a mean survival of 21.7 months in patients
treated with DEB-TACE, which was less than the 41 months in
the PH group in our study. The two studies used similar criteria
to enroll patients. Our study suggested that PH would produce
better overall survival than DEB.
It is controversial to perform partial hepatectomy (PH) on
hepatocellular carcinoma (HCC) patients with severe cirrhosis.
Thus, at the beginning of the study, severe cirrhosis and a low
platelet (PLT) were considered as exclusion criteria of the study.
In our study, the receiver operating characteristic curve for
PLT showed an optimal cut-off value of 121  109/L in detecting
death (area under the ROC curve = 0.415). In our study, univariate
analysis using the Log-rank test showed the variable for PLT
<121  109/L could not be entered into multivariate analysis,
according to our pre-set criteria (v2 = 3.287, p = 0.07). In response
to the criticism by Pang et al., in their Letter to the Editor, we car-
ried out another multivariate analysis to include PLT. The result
was still the same as with our previous conclusions: the type of
treatment, number of tumor, and gender were independent risk
factors associated with overall survival (OS). PLT was not an inde-
pendent risk factor (HR, 0.743; 95% CI, 0.485 to 1.136, p = 0.170).
Dr. Qing Pang and his associates stated in their letter that
patients with a high preoperative PLT had signiﬁcantly worse
OS and recurrence free survival (RFS). This statement was based
on a small sample size, retrospective clinical study, which was
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